|1.||Sirotnak, F M: 3 articles (10/2001 - 12/2000)|
|2.||Kris, M G: 2 articles (03/2001 - 12/2000)|
|3.||Frye, Debbie: 1 article (06/2007)|
|4.||Young, James A: 1 article (06/2007)|
|5.||Booser, Daniel: 1 article (06/2007)|
|6.||Rosenthal, Julian: 1 article (06/2007)|
|7.||Walters, Ronald: 1 article (06/2007)|
|8.||Gunale, Shivaji: 1 article (06/2007)|
|9.||Holmes, Frankie Ann: 1 article (06/2007)|
|10.||Gonzalez-Angulo, Ana M: 1 article (06/2007)|
11/01/1992 - "The increased therapeutic efficacy of Edatrexate is expected, because of the higher concentration of polyglutamates than MTX in tumor cells. "
01/01/2002 - "Phase I trial of edatrexate in advanced breast and other cancers."
01/01/1993 - "Due to the potential broad spectrum of activity of edatrexate plus CDDP, further studies are warranted to determine the mechanism responsible for the synergism and to investigate this combination in a variety of tumor models."
01/01/1993 - "These studies suggest that edatrexate may have a broad role in the treatment of solid tumors. "
10/01/1988 - "In this Phase I trial, we have treated 62 adults with advanced solid tumors, giving 10-EDAM i.v. on either a weekly x 3 schedule (35 patients) or a weekly schedule (27 patients). "
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/01/1995 - "Edatrexate studies in non-small cell lung cancer."
01/01/1992 - "Phase II study of Edatrexate in stage III and IV non-small-cell lung cancer."
08/01/1990 - "Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer."
03/01/1988 - "In this phase II trial, 20 patients with stage III or IV non-small-cell lung cancer (NSCLC) were administered 10-EDAM at a dose of 80 mg/m2 once weekly for 5 weeks. "
03/01/1988 - "Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer."
|3.||Breast Neoplasms (Breast Cancer)
06/01/2007 - "Phase II trial of 10-EDAM in the treatment of metastatic breast cancer."
07/01/1993 - "Edatrexate is an active agent against metastatic breast cancer, with acceptable toxicity. "
07/01/1993 - "Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study."
07/01/1992 - "A phase II trial of the new antifolate edatrexate (10-ethyl-10-deaza-aminopterin) was performed in thirty-eight patients with metastatic breast cancer who had never received chemotherapy. "
07/01/1992 - "Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer."
01/01/1998 - "2) Dose-limiting mucositis did not occur allowing escalation of edatrexate dose above levels previously achieved with this edatrexate dose schedule. "
03/01/2001 - "On schedule B, the maximum tolerated dose of biweekly edatrexate was 80 mg/m2, with leukopenia and mucositis as dose limiting. "
03/01/2001 - "On schedule A, the maximum tolerated dose of weekly edatrexate was 40 mg/m2, with dose-limiting toxicities of leukopenia, mucositis, and renal insufficiency. "
01/01/1997 - "This study suggests that ice-chip cryotherapy is effective in reducing the severity of mucositis typically associated with this edatrexate schedule of administration. "
01/01/1998 - "Based on the short initial plasma half-life of edatrexate, prophylactic ice chip cryotherapy was used to reduce the severity of mucositis. "
|5.||Hepatocellular Carcinoma (Hepatoma)
09/01/1994 - "Edatrexate administered at this dose and schedule appears to have little therapeutic efficacy against advanced hepatocellular carcinoma."
09/01/1994 - "A phase II trial of edatrexate was conducted in patients with advanced hepatocellular carcinoma. "
09/01/1994 - "Phase II trial of edatrexate in patients with advanced hepatocellular carcinoma."
|3.||Leucovorin (Folinic Acid)
|7.||Folic Acid (Vitamin M)
|8.||Vinblastine (Vinblastine Sulfate)
|1.||Cryotherapy (Therapy, Cold)
|2.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)
|4.||Combination Drug Therapy (Combination Chemotherapy)